Preload Image
Preload Image
Report Store mobile icon
Europe Influenza Treatment Market Outlook, 2030

Europe Influenza Treatment Market Outlook, 2030

2025

Europe Influenza Treatment Market Outlook, 2030

The Europe influenza treatment market was valued at $187M, supported by seasonal demand and government healthcare initiatives.

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The European Influenza Treatment Market is experiencing significant growth, driven by a confluence of factors including the rising incidence of influenza infections, increasing awareness about the disease, and advancements in treatment options. The market is witnessing a surge in demand for antiviral medications, which are crucial for managing influenza and preventing complications. This increased demand is fueled by the heightened prevalence of both influenza A and B strains across Europe. Furthermore, the market is benefiting from the growing emphasis on preventive measures, such as vaccination campaigns and public health initiatives promoting hygiene and early diagnosis. The presence of a well-established healthcare infrastructure and easy access to antiviral drugs in many European countries further contribute to market expansion. Additionally, ongoing research and development efforts are focused on introducing more effective and convenient treatment options, such as novel antiviral drugs with improved efficacy and shorter treatment durations. These advancements are expected to further propel the growth of the European Influenza Treatment Market in the coming years.

Europe influenza treatment market accounted for $187.6 million in 2019 and will grow by 3.6% annually over 2020-2030 owing to the rising incidences of influenza, growing awareness and need for new drugs and treatment amid COVID-19 pandemic. The European Influenza Treatment Market is dynamic, shaped by several key trends, drivers, and trade programs. A prominent trend is the increasing preference for novel antiviral drugs with improved efficacy and shorter treatment durations, driving research and development in this area. Market growth is primarily fueled by the rising incidence of influenza infections, coupled with growing public awareness of the disease and its potential complications. This awareness translates into increased demand for both preventive measures like vaccination and effective treatments. Furthermore, the well-established healthcare infrastructure across Europe, providing easy access to antiviral medications, significantly contributes to market expansion. Trade programs within the European Union facilitate the seamless distribution of these treatments, ensuring availability across member states. These programs often involve collaborations between pharmaceutical companies, healthcare providers, and government agencies to ensure timely access to essential medicines. Additionally, public health initiatives promoting early diagnosis and treatment of influenza play a crucial role in driving market growth. These initiatives often include educational campaigns, free or subsidized vaccination programs, and readily available diagnostic tools. The market is also influenced by the constant evolution of influenza viruses, necessitating ongoing research to develop new and effective treatments against emerging strains. This continuous need for updated therapies further fuels market growth and innovation. In conclusion, the European Influenza Treatment Market is a vibrant landscape driven by a combination of epidemiological factors, public health initiatives, technological advancements, and robust trade programs, all contributing to improved management of influenza across the region.
The European Influenza Treatment Market offers a range of product types designed to combat influenza infections, primarily focusing on antiviral medications. These antiviral drugs can be broadly categorized into two main classes: neuraminidase inhibitors and cap-dependent endonuclease inhibitors. Neuraminidase inhibitors, such as oseltamivir (Tamiflu) and zanamivir (Relenza), are the most commonly prescribed antiviral medications for influenza. They work by preventing the release of newly formed virus particles from infected cells, thereby limiting the spread of the virus within the body. Oseltamivir is administered orally, while zanamivir is inhaled. Another class of antiviral drugs, known as cap-dependent endonuclease inhibitors, includes baloxavir marboxil (Xofluza). This newer medication works by targeting a different mechanism in the influenza virus replication process. Baloxavir marboxil is administered as a single oral dose, offering a more convenient treatment option compared to the multi-day regimens of neuraminidase inhibitors. In addition to these antiviral medications, other product types available in the market include over-the-counter medications aimed at relieving influenza symptoms, such as fever reducers and cough suppressants. However, these medications do not target the virus itself and are primarily used for symptomatic relief. The choice of product type depends on various factors, including the severity of the infection, the patient's age and health condition, and the specific strain of influenza virus involved. Healthcare professionals play a crucial role in determining the most appropriate treatment approach for each individual case, considering the available options and their respective benefits and risks.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The European Influenza Treatment Market addresses two primary types of influenza viruses: influenza A and influenza B. Influenza A viruses are further categorized into subtypes based on two surface proteins: hemagglutinin (HA) and neuraminidase (NA). These subtypes are named according to the specific HA and NA proteins they possess, such as H1N1 or H3N2. Influenza A viruses are known for their ability to mutate and evolve rapidly, leading to the emergence of new strains that can cause seasonal epidemics and even pandemics. Influenza B viruses, on the other hand, are not classified into subtypes but can be further divided into lineages, such as Victoria and Yamagata. Influenza B viruses generally exhibit a slower rate of mutation compared to influenza A viruses. Both influenza A and B viruses can cause similar symptoms, including fever, cough, sore throat, muscle aches, and fatigue. However, influenza A infections are often associated with more severe illness and a higher risk of complications, particularly in vulnerable populations such as the elderly, young children, and individuals with underlying health conditions. The European Influenza Treatment Market caters to both influenza A and B infections, offering antiviral medications that are effective against both types of viruses. These antiviral drugs work by targeting specific mechanisms in the influenza virus replication process, thereby limiting the severity and duration of the illness. Healthcare professionals play a vital role in diagnosing the specific type of influenza virus and determining the most appropriate treatment approach for each individual case.

The European Influenza Treatment Market offers a variety of administration routes for antiviral medications, each with its own advantages and disadvantages. The most common route of administration is oral, which includes tablets and capsules. Oral medications are convenient and easy to administer, making them a popular choice for many patients. However, some individuals may experience difficulty swallowing pills or may have gastrointestinal issues that limit their ability to absorb medications effectively. Another route of administration is inhalation, which involves inhaling the medication through a nebulizer or inhaler. Inhaled medications can deliver the drug directly to the respiratory tract, where the influenza virus primarily replicates. This can be particularly beneficial for individuals with respiratory conditions such as asthma or chronic obstructive pulmonary disease (COPD). However, inhaled medications may require special equipment and coordination, which can be challenging for some patients. In addition to oral and inhalation routes, some antiviral medications can also be administered intravenously. Intravenous administration involves injecting the medication directly into a vein, allowing for rapid delivery and precise dosing. Intravenous medications are typically reserved for hospitalized patients with severe influenza infections or those who are unable to take oral or inhaled medications. The choice of administration route depends on various factors, including the patient's age, health condition, the severity of the infection, and the specific antiviral medication being used. Healthcare professionals play a crucial role in determining the most appropriate administration route for each individual case, considering the available options and their respective benefits and risks.

The European Influenza Treatment Market utilizes a variety of distribution channels to ensure that antiviral medications reach patients in a timely and efficient manner. The primary distribution channels include retail pharmacies, hospital pharmacies, and online pharmacies. Retail pharmacies, which are commonly found in communities across Europe, play a significant role in dispensing antiviral medications to patients with influenza. These pharmacies often have trained pharmacists who can provide guidance on the appropriate use of medications and answer any questions patients may have. Hospital pharmacies, located within hospitals and medical facilities, are responsible for supplying antiviral medications to hospitalized patients with influenza. Hospital pharmacies also play a crucial role in managing influenza outbreaks within healthcare settings and ensuring that healthcare professionals have access to the necessary medications. In recent years, online pharmacies have emerged as a growing distribution channel for influenza treatments. Online pharmacies offer a convenient way for patients to order medications from the comfort of their homes, particularly for those who may have difficulty accessing traditional pharmacies. However, it is important to ensure that online pharmacies are licensed and reputable to avoid counterfeit or substandard medications. The choice of distribution channel may depend on various factors, such as the patient's location, the urgency of the situation, and the availability of specific medications. Healthcare professionals can help patients navigate the different distribution channels and ensure that they receive the most appropriate treatment in a timely manner.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



The European Influenza Treatment Market encompasses a diverse range of countries and sub-regions, each with its own healthcare systems, demographics, and influenza prevalence patterns. Western Europe, including countries like Germany, France, and the United Kingdom, generally has well-established healthcare infrastructure and high awareness of influenza and its treatment. These countries often have robust public health initiatives and readily available access to antiviral medications. Southern Europe, encompassing countries like Italy, Spain, and Greece, may have varying levels of healthcare access and awareness but still represents a significant market for influenza treatments. Eastern Europe, including countries like Poland, Hungary, and Russia, is experiencing growing awareness of influenza and increasing access to modern treatments, contributing to the expansion of the market in this region. The Nordic countries, such as Sweden, Norway, and Denmark, are known for their strong focus on public health and preventive care, with high vaccination rates and well-established systems for managing influenza. Each region within Europe may have specific challenges and opportunities related to influenza treatment, such as varying prevalence of different influenza strains, different healthcare policies, and cultural factors that influence healthcare-seeking behavior. Understanding these regional nuances is crucial for pharmaceutical companies and healthcare providers to effectively address the needs of patients with influenza across Europe.


Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Introduction 6
  • 1.1 Industry Definition and Research Scope 6
  • 1.1.1 Industry Definition 6
  • 1.1.2 Research Scope 7
  • 1.2 Research Methodology 10
  • 1.2.1 Overview of Market Research Methodology 10
  • 1.2.2 Market Assumption 11
  • 1.2.3 Secondary Data 11
  • 1.2.4 Primary Data 11
  • 1.2.5 Data Filtration and Model Design 13
  • 1.2.6 Market Size/Share Estimation 14
  • 1.2.7 Research Limitations 15
  • 1.3 Executive Summary 16
  • 2 Market Overview and Dynamics 19
  • 2.1 Market Size and Forecast 19
  • 2.1.1 Impact of COVID-19 on the Market 20
  • 2.2 Major Growth Drivers 22
  • 2.3 Market Restraints and Challenges 26
  • 2.4 Emerging Opportunities and Market Trends 29
  • 2.5 Porter’s Fiver Forces Analysis 33
  • 3 Segmentation of Europe Market by Product Type 37
  • 3.1 Market Overview by Product Type 37
  • 3.2 Oseltamivir Phosphate 39
  • 3.3 Baloxavir Marboxil 40
  • 3.4 Peramivir 41
  • 3.5 Zanamivir 42
  • 3.6 Other Drugs 43
  • 4 Segmentation of Europe Market by Influenza Type 44
  • 4.1 Market Overview by Influenza Type 44
  • 4.2 Influenza A 46
  • 4.3 Influenza B 47
  • 4.4 Influenza C 48
  • 5 Segmentation of Europe Market by Administration Route 49
  • 5.1 Market Overview by Administration Route 49
  • 5.2 Oral Administration 51
  • 5.3 Other Administration Routes 52
  • 6 Segmentation of Europe Market by Distribution Channel 53
  • 6.1 Market Overview by Distribution Channel 53
  • 6.2 Retail Pharmacy 55
  • 6.3 Hospital Pharmacy 56
  • 6.4 Clinics 57
  • 6.5 Online Stores 58
  • 7 European Market 2019-2030 by Country 59
  • 7.1 Overview of European Market 59
  • 7.2 Germany 62
  • 7.3 UK 64
  • 7.4 France 67
  • 7.5 Spain 69
  • 7.6 Italy 71
  • 7.7 Russia 73
  • 7.8 Rest of European Market 75
  • 8 Competitive Landscape 77
  • 8.1 Overview of Key Vendors 77
  • 8.2 New Product Launch, Partnership, Investment, and M&A 80
  • 8.3 Company Profiles 81
  • AstraZeneca Plc 81
  • BioCryst Pharmaceuticals Inc. 83
  • Biondvax 84
  • Daiichi Sankyo Company 85
  • F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) 86
  • GlaxoSmithKline Plc 87
  • Mylan N.V 88
  • Natco Pharma Limited 89
  • Novartis AG 90
  • Sanofi 91
  • Seqirus 92
  • Teva Pharmaceutical Industries Limited 93
  • 9 Investing in Europe Market: Risk Assessment and Management 94
  • 9.1 Risk Evaluation of Europe Market 94
  • 9.2 Critical Success Factors (CSFs) 97
  • Related Reports and Products 100

Table 1. Snapshot of Global Digital Biomarkers Market, 2019-2030 21
Table 2. Overview of Traditional and Digital Biomarker Features, Novel Applications, and Published Examples 25
Table 3. World Smartphone Connections, Average Network Connection Speed for Smartphones and Tablets, 2019-2030 33
Table 4. World Mobile Data Traffic by Deployment Mode, 2019-2030, EB/year 34
Table 5. World Mobile Data Traffic by Device, 2019-2030, EB/year 34
Table 6. Current Challenges of Digital Biomarkers in Medical Settings 37
Table 7. Main Product Trends and Market Opportunities in Global Digital Biomarkers Market 40
Table 8. Global Digital Biomarkers Market by System Component, 2019-2030, $ mn 48
Table 9. Global Digital Biomarkers Market: Data Collection Tools by Type, 2019-2030, $ mn 51
Table 10. Global Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 58
Table 11. Global Digital Biomarkers Market: Neurodegenerative Disorders by Type, 2019-2030, $ mn 62
Table 12. Global Digital Biomarkers Market by Application, 2019-2030, $ mn 73
Table 13. Global Digital Biomarkers Market by Development Status, 2019-2030, $ mn 81
Table 14. Global Digital Biomarkers Market by End User, 2019-2030, $ mn 86
Table 15. Global Digital Biomarkers Market by Region, 2019-2030, $ mn 92
Table 16. Leading National Digital Biomarkers Market, 2019 and 2030, $ mn 94
Table 17. North America Digital Biomarkers Market by Country, 2019-2030, $ mn 97
Table 18. U.S. Digital Biomarkers Market by System Component, 2019-2030, $ mn 101
Table 19. U.S. Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 101
Table 20. U.S. Digital Biomarkers Market by End User, 2019-2030, $ mn 101
Table 21. Canada Digital Biomarkers Market by System Component, 2019-2030, $ mn 104
Table 22. Canada Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 104
Table 23. Canada Digital Biomarkers Market by End User, 2019-2030, $ mn 104
Table 24. Mexico Digital Biomarkers Market by System Component, 2019-2030, $ mn 106
Table 25. Mexico Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 106
Table 26. Mexico Digital Biomarkers Market by End User, 2019-2030, $ mn 106
Table 27. Europe Digital Biomarkers Market by Country, 2019-2030, $ mn 110
Table 28. Germany Digital Biomarkers Market by System Component, 2019-2030, $ mn 112
Table 29. Germany Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 112
Table 30. Germany Digital Biomarkers Market by End User, 2019-2030, $ mn 112
Table 31. UK Digital Biomarkers Market by System Component, 2019-2030, $ mn 114
Table 32. UK Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 114
Table 33. UK Digital Biomarkers Market by End User, 2019-2030, $ mn 114
Table 34. France Digital Biomarkers Market by System Component, 2019-2030, $ mn 116
Table 35. France Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 116
Table 36. France Digital Biomarkers Market by End User, 2019-2030, $ mn 116
Table 37. Netherlands Digital Biomarkers Market by System Component, 2019-2030, $ mn 118
Table 38. Netherlands Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 118
Table 39. Netherlands Digital Biomarkers Market by End User, 2019-2030, $ mn 118
Table 40. Italy Digital Biomarkers Market by System Component, 2019-2030, $ mn 120
Table 41. Italy Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 120
Table 42. Italy Digital Biomarkers Market by End User, 2019-2030, $ mn 120
Table 43. Russia Digital Biomarkers Market by System Component, 2019-2030, $ mn 122
Table 44. Russia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 122
Table 45. Russia Digital Biomarkers Market by End User, 2019-2030, $ mn 122
Table 46. Digital Biomarkers Market in Rest of Europe by Country, 2019-2030, $ mn 124
Table 47. APAC Digital Biomarkers Market by Country, 2019-2030, $ mn 127
Table 48. Japan Digital Biomarkers Market by System Component, 2019-2030, $ mn 131
Table 49. Japan Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 131
Table 50. Japan Digital Biomarkers Market by End User, 2019-2030, $ mn 131
Table 51. China Digital Biomarkers Market by System Component, 2019-2030, $ mn 133
Table 52. China Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 133
Table 53. China Digital Biomarkers Market by End User, 2019-2030, $ mn 133
Table 54. Australia Digital Biomarkers Market by System Component, 2019-2030, $ mn 135
Table 55. Australia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 135
Table 56. Australia Digital Biomarkers Market by End User, 2019-2030, $ mn 135
Table 57. India Digital Biomarkers Market by System Component, 2019-2030, $ mn 137
Table 58. India Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 137
Table 59. India Digital Biomarkers Market by End User, 2019-2030, $ mn 137
Table 60. South Korea Digital Biomarkers Market by System Component, 2019-2030, $ mn 139
Table 61. South Korea Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 139
Table 62. South Korea Digital Biomarkers Market by End User, 2019-2030, $ mn 139
Table 63. Digital Biomarkers Market in Rest of APAC by Country, 2019-2030, $ mn 141
Table 64. South America Digital Biomarkers Market by Country, 2019-2030, $ mn 144
Table 65. Argentina Digital Biomarkers Market by System Component, 2019-2030, $ mn 146
Table 66. Argentina Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 146
Table 67. Argentina Digital Biomarkers Market by End User, 2019-2030, $ mn 146
Table 68. Brazil Digital Biomarkers Market by System Component, 2019-2030, $ mn 148
Table 69. Brazil Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 148
Table 70. Brazil Digital Biomarkers Market by End User, 2019-2030, $ mn 148
Table 71. Chile Digital Biomarkers Market by System Component, 2019-2030, $ mn 150
Table 72. Chile Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 150
Table 73. Chile Digital Biomarkers Market by End User, 2019-2030, $ mn 150
Table 74. MEA Digital Biomarkers Market by Country, 2019-2030, $ mn 154
Table 75. UAE Digital Biomarkers Market by System Component, 2019-2030, $ mn 156
Table 76. UAE Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 156
Table 77. UAE Digital Biomarkers Market by End User, 2019-2030, $ mn 156
Table 78. Saudi Arabia Digital Biomarkers Market by System Component, 2019-2030, $ mn 158
Table 79. Saudi Arabia Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 158
Table 80. Saudi Arabia Digital Biomarkers Market by End User, 2019-2030, $ mn 158
Table 81. Israel Digital Biomarkers Market by System Component, 2019-2030, $ mn 160
Table 82. Israel Digital Biomarkers Market by Therapeutic Area, 2019-2030, $ mn 160
Table 83. Israel Digital Biomarkers Market by End User, 2019-2030, $ mn 160
Table 84. Breakdown of Global Market by Key Vendor, 2019, % 164
Table 85. Actigraph LLC: Company Snapshot 167
Table 86. Actigraph LLC: Business Segmentation 167
Table 87. Actigraph LLC: Product Portfolio 168
Table 88. Actigraph LLC: Revenue, 2016-2018, $ mn 168
Table 89. Actigraph LLC: Recent Developments 168
Table 90. Risk Evaluation for Investing in Global Market, 2019-2030 197
Table 91. Critical Success Factors and Key Takeaways 200

Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 5. Europe Influenza Treatment Market, 2019-2030, $ mn 19
Figure 6. Impact of COVID-19 on Business 20
Figure 7. Primary Drivers and Impact Factors of Europe Influenza Treatment Market 22
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 25
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 25
Figure 10. Primary Restraints and Impact Factors of Europe Influenza Treatment Market 26
Figure 11. Investment Opportunity Analysis 30
Figure 12. Porter’s Fiver Forces Analysis of Europe Influenza Treatment Market 33
Figure 13. Breakdown of Europe Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 37
Figure 14. Europe Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%) 38
Figure 15. Europe Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn 39
Figure 16. Europe Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn 40
Figure 17. Europe Influenza Treatment Market: Peramivir, 2019-2030, $ mn 41
Figure 18. Europe Influenza Treatment Market: Zanamivir, 2019-2030, $ mn 42
Figure 19. Europe Influenza Treatment Market: Other Drugs, 2019-2030, $ mn 43
Figure 20. Breakdown of Europe Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 44
Figure 21. Europe Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%) 45
Figure 22. Europe Influenza Treatment Market: Influenza A, 2019-2030, $ mn 46
Figure 23. Europe Influenza Treatment Market: Influenza B, 2019-2030, $ mn 47
Figure 24. Europe Influenza Treatment Market: Influenza C, 2019-2030, $ mn 48
Figure 25. Breakdown of Europe Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 49
Figure 26. Europe Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%) 50
Figure 27. Europe Influenza Treatment Market: Oral Administration, 2019-2030, $ mn 51
Figure 28. Europe Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn 52
Figure 29. Breakdown of Europe Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 53
Figure 30. Europe Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%) 54
Figure 31. Europe Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn 55
Figure 32. Europe Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn 56
Figure 33. Europe Influenza Treatment Market: Clinics, 2019-2030, $ mn 57
Figure 34. Europe Influenza Treatment Market: Online Stores, 2019-2030, $ mn 58
Figure 35. Breakdown of European Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 60
Figure 36. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 61
Figure 37. Influenza Treatment Market in Germany, 2019-2030, $ mn 62
Figure 38. Influenza Treatment Market in UK, 2019-2030, $ mn 64
Figure 39. Influenza Treatment Market in France, 2019-2030, $ mn 67
Figure 40. Influenza Treatment Market in Spain, 2019-2030, $ mn 69
Figure 41. Influenza Treatment Market in Italy, 2019-2030, $ mn 71
Figure 42. Influenza Treatment Market in Russia, 2019-2030, $ mn 73
Figure 43. Influenza Treatment Market in Rest of Europe, 2019-2030, $ mn 75
Figure 44. Growth Stage of Europe Influenza Treatment Industry over the Forecast Period 77

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (09 May, 2026)
  • Notify To Team (09 May, 2026)
  • Report updation (10 May, 2026)
  • Report Quality Check (10 May, 2026)
  • Report Dispatch (11 May, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Europe Influenza Treatment Market Outlook, 2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.